Former Dendreon CEO Mitch Gold Returns to Public Biotech Stage with Cancer Immunotherapy Merger – TheStreet.com
Xconomy |
Former Dendreon CEO Mitch Gold Returns to Public Biotech Stage with Cancer Immunotherapy Merger
TheStreet.com Once the merger is complete in the third quarter, the combined companies will take the Alpine Immune Sciences name and focus on its pipeline of protein-based immunotherapy drugs. Alpine will have $90 million in funding with shares trading on the Nasdaq. Ex-Dendreon CEO, Gold, Returns to Wall Street as Alpine, Nivalis Merge Colorado biotech firm is being acquired to create $90M company in Seattle |
